M
IMEPro
M72.0 Musculoskeletal
Updated March 2026

Palmar fascial fibromatosis (Dupuytren)

ICD-10 Code: M72.0 · Body Part: Wrist/Hand

QME Evaluation Process

Hand examination for nodules and contracture, finger ROM testing. UE impairment based on digit flexion contracture severity.

Typical Impairment Rating

3-12% UE (2-7% WPI) based on contracture severity

AMA Guides Edition

5th Edition

Common Treatments

+ Collagenase injection
+ Needle aponeurotomy
+ Fasciectomy

Related Conditions

Body Part Guide

Wrist/Hand Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Palmar fascial fibromatosis (Dupuytren)

Find a QME Specialist

Browse QME-certified physicians who evaluate palmar fascial fibromatosis (dupuytren) and related wrist/hand conditions in California.

Browse Physical Medicine & Rehabilitation Physicians →

Frequently Asked Questions

What is Palmar fascial fibromatosis (Dupuytren) (M72.0)?

Palmar fascial fibromatosis (Dupuytren) is an ICD-10 diagnosis code (M72.0) classified under Musculoskeletal conditions. It affects the Wrist/Hand and is occasionally seen in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is M72.0 rated for impairment?

The typical whole person impairment (WPI) range for Palmar fascial fibromatosis (Dupuytren) is 3-12% UE (2-7% WPI) based on contracture severity. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for M72.0?

Hand examination for nodules and contracture, finger ROM testing. UE impairment based on digit flexion contracture severity.

What treatments are common for Palmar fascial fibromatosis (Dupuytren)?

Common treatments for Palmar fascial fibromatosis (Dupuytren) include Collagenase injection, Needle aponeurotomy, Fasciectomy. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.